スポンサーリンク
Department Of Clinical Genetic Oncology Cancer Institute Hospital Japanese Foundation For Cancer Res | 論文
- Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer
- Bilateral Nonpalpable Breast Carcinomas in a Patient with BRCA2 Germ Line Mutation and Past History of Osteosarcoma
- 癌抑制遺伝子BRCA1/2の機能およびPARP阻害剤によるBRCA変異陽性乳癌の治療 (特集 癌治療・発癌・老化の鍵を握るDNA修復経路)
- Familial breast and ovarian cancers
- Analysis of extracellular matrix of a skin tumor from patients with juvenile hyaline fibromatosis
- Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer
- Novel BRCA2-interacting protein BJ-HCC-20A inhibits the induction of apoptosis in response to DNA damage
- The cell death machinery governed by the p53 tumor suppressor in response to DNA damage
- 遺伝子診断の展望 (乳癌--基礎・臨床研究のアップデート) -- (臨床研究 診断 遺伝子診断)
- Functional pathway characterized by gene expression analysis of supraclavicular lymph node metastasis-positive breast cancer
- Mutation Analysis of the mel-18 Gene that Shows Decreased Expression in Human Breast Cancer Cell Lines
- Molecular markers associated with lymph node metastasis in pancreatic ductal adenocarcinoma by genome-wide expression profiling
- Retrotransposal integration of mobile genetic elements in human diseases
- Mutational Analysis of the p53 and K-ras Genes and Allelotype Study of the Rb-1 Gene for Investigating the Pathogenesis of Combined Hepatocellular-Cholangiocellular Carcinomas
- Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage
- Gene expression-based diagnosis of efficacy of chemotherapy for breast cancer
- BRCA2 interacts with the cytoskeletal linker protein plectin to form a complex controlling centrosome localization
- 遺伝性乳癌・卵巣癌の遺伝子診断および研究の現状 (特集 婦人科における遺伝性腫瘍の取扱いの実際)
- Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer
- Prospective randomized phase II study determines the clinical usefulness of genetic biomarkers for sensitivity to primary chemotherapy with paclitaxel in breast cancer